Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 16, 2016 for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
News
-
-
On March 10, 2017, the PTAB published a decision terminating the proceedings in IPR2016-1693 and IPR2016-1694 because the parties have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepsis UK Limited (“Samsung”), Biogen Idec Limited (“Biogen”), and Fujifilm Kyowa Kirin Biologic Company Limited...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 2, 2017, the PTAB issued a decision denying Celltrion, Inc.’s (“Celltrion”) request for inter partes review (“IPR”) of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Inter partes review (“IPR”) is one of several post-grant procedures created by the Leahy Smith America Invents Act (“AIA”). An...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on August 15, 2016 for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion’s Truxima (CT-P10, rituximab), a biosimilar to Rituxan® received approval from the European Commission on February 22, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on February 21, 2017 for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA has accepted for review an application submitted by Mylan N.V. (“Mylan”) and Biocon Ltd. (“Biocon”) under the 351(k)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]